Biogen Inc
NAS : BIIB$232.65+1.76%Oct 16 close
Financials
Income statement · full history
USD in millions · per-share amounts unscaled. Each period shows the value from the latest filing that prints it.
| Reported line item | Jan 1, 2017 to Dec 31, 2017 | Jan 1, 2018 to Dec 31, 2018 | Jan 1, 2019 to Dec 31, 2019 | Jan 1, 2020 to Dec 31, 2020 | Jan 1, 2021 to Dec 31, 2021 | Jan 1, 2022 to Dec 31, 2022 | Jan 1, 2023 to Dec 31, 2023 | Jan 1, 2024 to Dec 31, 2024 | Jan 1, 2025 to Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenues | 12,273.9 | 13,452.9 | 14,377.9 | 13,444.6 | 10,981.7 | 10,173.4 | 9,835.6 | 9,675.9 | 9,890.6 |
| Cost of sales, excluding amortization and impairment of acquired intangible assets | 1,630 | 1,816.3 | 1,955.4 | 1,805.2 | 2,109.7 | 2,278.3 | 2,533.4 | 2,310.4 | 2,404.2 |
| Research and development | 2,253.6 | 2,597.2 | 2,280.6 | 3,990.9 | 2,501.2 | 2,231.1 | 2,445.4R | 1,980.3R | 1,778.6 |
| Acquired in-process research and development, upfront and milestone expense | 16.6 | 61.5 | 471.8 | ||||||
| Selling, general and administrative | 1,933.9R | 2,106.3 | 2,374.7 | 2,504.5 | 2,674.3 | 2,403.6 | 2,549.7 | 2,403.7 | 2,433.6 |
| Amortization and impairment of acquired intangible assets | 814.7 | 747.3 | 489.9 | 464.8 | 881.3 | 365.9 | 240.6 | 446.7 | 515 |
| Collaboration profit sharing/(loss reimbursement) | 112.3 | 185 | 241.6 | 232.9 | 7.2 | (7.4) | 218.8 | 254.4 | 290.2 |
| (Gain) loss on fair value remeasurement of contingent consideration | 62.7 | (12.3) | (63.7) | (86.3) | (50.7) | (209.1) | 0 | 27.7 | 33.6 |
| (Gain) loss on divestiture of Hillerd, Denmark manufacturing operationsno longer reported | 0 | 0 | 55.3 | (92.5) | 0 | 0 | |||
| Impairment of ROU asset | 0 | 0 | 52.9 | ||||||
| Acquired in-process research and developmentno longer reported | 120 | 112.5 | 0 | 75 | 18 | 0 | 0 | ||
| Restructuring charges | 0.9 | 12 | 1.5 | 0 | 0 | 131.1 | 218.8 | 30.2 | 48.6 |
| Gain on sale of priority review voucher, net | 0 | 0 | (88.6) | 0 | |||||
| Other (income) expense, net | (217)R | 11 | 83.3 | (497.4) | 1,095.5 | (108.2) | 315.5 | 343.6 | 305.6 |
| Gain on sale of building, netno longer reported | 0 | 0 | (503.7) | 0 | 0 | ||||
| Total cost and expense | 6,928.1R | 7,564.3 | 7,335.3 | 8,397.1R | 9,236.5R | 6,581.6 | 8,538.8 | 7,769.9 | 8,334.1 |
| Income before income tax (benefit) expense | 5,128.8 | 5,899.6 | 7,125.9 | 5,047.5 | 1,745.2 | 3,591.8 | 1,296.8 | 1,906 | 1,556.5 |
| Income from operationsno longer reported | 5,345.8R | 5,888.6 | 7,042.6 | 4,550.1 | 2,840.7 | ||||
| Income tax (benefit) expense | 2,458.7 | 1,425.6 | 1,158 | 992.3 | 52.5 | 632.8 | 135.3 | 273.8 | 263.6 |
| Net income | 2,670.1 | 4,474 | 5,888.5 | 4,060.5 | 1,727.6 | 2,961.6 | 1,161.5 | 1,632.2 | 1,292.9 |
| Equity in (income) loss of investee, net of taxno longer reported | 0 | 79.4 | (5.3) | (34.9) | (2.6) | 0 | 0 | ||
| Equity in loss of investee, net of taxno longer reported | 0 | 0 | 79.4 | ||||||
| Net income attributable to noncontrolling interests, net of tax | 131 | 43.3 | 0 | 59.9 | 171.5 | (85.3) | 0.4 | 0 | 0 |
| Net income attributable to Biogen Inc. | 2,539.1 | 4,430.7 | 5,888.5 | 4,000.6 | 1,556.1 | 3,046.9 | 1,161.1 | 1,632.2 | 1,292.9 |
| Basic earnings per share attributable to Biogen Inc. (in dollars per share) | 11.94 | 21.63 | 31.47 | 24.86 | 10.44 | 20.96 | 8.02 | 11.21 | 8.83 |
| Diluted earnings per share attributable to Biogen Inc. (in dollars per share) | 11.92 | 21.58 | 31.42 | 24.80 | 10.40 | 20.87 | 7.97 | 11.18 | 8.79 |
| Weighted-average number of common shares outstanding (in shares) | 212.6 | 204.9 | 187.1 | 160.9 | 149.1 | 145.3 | 144.7 | 145.6 | 146.5 |
| Diluted earnings per share attributable to Biogen Inc. (in shares) | 213 | 205.3 | 187.4 | 161.3 | 149.6 | 146 | 145.6 | 145.9 | 147.1 |
History starts FY2017, the period ended Dec 31, 2017 — the earliest period our structured-data source covers, not the company’s first year.
28 reported lines · 9 periods · values taken from the latest filing that prints each period.
- R8 restated by the filer — hover for the figure as first reported.
- italic12 from an earlier filing than the rest of the column.
- no longer reported6 lines the filer stopped printing.
- — the filer printed the line and left the period empty. An empty cell means the line was not printed at all; it is never a zero.
214 of 214 values link to the exact element in the filer’s own document.
Every line and every caption is the company’s own. Each period carries the value from the latest filing that prints it, which is why a restated period shows the restated number with the figure as first reported kept underneath.
Nothing on this table is computed by us: no fourth quarter, no growth rate, no margin. Marks describe the filer’s own restatements.